Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech ...

Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members at ...

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current ...

Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more ...

The starting dose of 0.25 mg will now cost Rs 2,712 per week, down from Rs 4,336 earlier, with the new prices effective ...

Novo Nordisk, the global healthcare leader in the treatment of chronic diseases such as diabetes and obesity, has announced ...

Norway’s sovereign wealth fund said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk’s extraordinary shareholders’ meeting on November 14.

The Novo Nordisk Foundation in Denmark, one of the world’s leading funders of pharmaceutical and biotechnology research, is investing €21.7 million to support emerging and rising Danish researchers in ...

Novo Nordisk stock rose 2.6% after withdrawing from a $10 billion bidding war for Metsera that investors viewed as too ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo ...